Clinical Trial

Percutaneous Biopsy After Neoadjuvant Chemotherapy.

Study acronym: VAC-Biopsy
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Neoadjuvant chemotherapy is widely used in the treatment of locally advanced breast cancer or in early stages of triple-negative or HER2 overexpressing tumors. Pathological complete response (pCR) to neoadjuvant chemotherapy is associated with better clinical outcomes. However, confirmation of pCR still depends on surgery, which may represent overtreatment for some patients. In this context, image-guided vacuum-assisted percutaneous biopsy (VAB) has been investigated as an alternative to assess tumor response and potentially avoid breast surgery in the future. However, there are no studies evaluating this strategy in brazilian patients, the majority of whom present with locally advanced tumors at diagnosis.
Trial Details
NCT Number NCT07644455
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions Breast Cancer
Enrollment 100 participants
Start Date 2026-06
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12